Уноси

• SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (2015-06)

  J. Choe, N. Prodanović, j. Niebrizidovski, i. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zielinska, J. Choe, Y. Rho, J. Smolen, SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, Jun, 2015

• Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results (2017)

  J. Smolen, J. Choe, N. Prodanović, J. Niebrizidovski, I. Staikov, E. Dokoupilova, A. Baranauskaite, R. Iatsishin, M. Mekić, V. Poravska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, I. Lee, I. Rho, Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results, RHEUMATOLOGY, pp. 10 - 10, 2017